Ideation 2019

Ideation 2019 pub-01.jpg


Ideation 2019 will take place on April 22nd, 2019 from 6-9PM in the Ray and Maria Stata Center 32-123 at MIT.

Interested in Attending Ideation 2019?

Even if you are not pitching, you are welcome to attend Ideation 2019. Tickets will be available until 5pm on 4/22 or until sold out.

Event Schedule

An Eventbrite reservation (free) is required to attend the event. Doors will open at 5:30, after which guests can check-in at the front desk. After 5:45pm, entrance to the event will be on a first come, first served basis. Note based on RSVPs and past attendance, we expect to reach capacity and recommend arriving before 5:45 to guarantee a seat!

5:30pm                 Doors Open

6:00pm                 Introduction of Ideation and 2019 Speakers

6:10pm                 Talk by Dr. Robert Langer

6:45pm                 Talks by the Dr. Jonathan Gilbert, Dr. Eric Kelsic, Dr. Omar Obudayyeh, Dr. Jonathan Gootenberg

7:25pm                 Team Pitches

8:00-9:00pm        Networking with teams and representatives from partnering organizations (food provided)

2019 Speakers

Dr. Robert S. Langer  is the David H. Koch Institute Professor at MIT and is considered “one of history’s most prolific inventors in medicine”. He has authored more than 1,400 articles and has over 1,300 issued and pending patents worldwide. Dr. Langer is the most cited engineer in history and has licensed his patents to over 350 pharmaceutical, chemical, biotechnology and medical device companies. Dr. Langer has received numerous major awards and medals including the United States Nation Medal of Science (2006), the United States Nation Medal of Technology and Innovation (2011) the Lemelson-MIT Prize (the world’s largest prize for invention) (1998) and he was recently named one of five U.S. Science Envoys for 2018. As a Science Envoy for Innovation, Dr. Langer will be focusing on novel approaches in biomaterials, drug delivery systems, nanotechnology, tissue engineering and the U.S approach to research commercialization.

Dr. Robert S. Langer is the David H. Koch Institute Professor at MIT and is considered “one of history’s most prolific inventors in medicine”. He has authored more than 1,400 articles and has over 1,300 issued and pending patents worldwide. Dr. Langer is the most cited engineer in history and has licensed his patents to over 350 pharmaceutical, chemical, biotechnology and medical device companies. Dr. Langer has received numerous major awards and medals including the United States Nation Medal of Science (2006), the United States Nation Medal of Technology and Innovation (2011) the Lemelson-MIT Prize (the world’s largest prize for invention) (1998) and he was recently named one of five U.S. Science Envoys for 2018. As a Science Envoy for Innovation, Dr. Langer will be focusing on novel approaches in biomaterials, drug delivery systems, nanotechnology, tissue engineering and the U.S approach to research commercialization.

Jonathan Gilbert, PhD  is the Head of Business Development at SQZ Biotech. SQZ Biotech uses a proprietary CellSqueeze platform to develop a new generation of unique cell therapies. The SQZ platform technology has the potential to revolutionize the treatment of many diseases and the company is currently focused on developing novel treatments for oncology and autoimmune diseases. Jonathan completed his PhD in chemical engineering at MIT under the co-mentorship of Professor Cohen, Professor Rubner and Professor Irivine and is one of SQZ's earliest employees.

Jonathan Gilbert, PhD is the Head of Business Development at SQZ Biotech. SQZ Biotech uses a proprietary CellSqueeze platform to develop a new generation of unique cell therapies. The SQZ platform technology has the potential to revolutionize the treatment of many diseases and the company is currently focused on developing novel treatments for oncology and autoimmune diseases. Jonathan completed his PhD in chemical engineering at MIT under the co-mentorship of Professor Cohen, Professor Rubner and Professor Irivine and is one of SQZ's earliest employees.

Eric Kelsic, PhD  is the Cofounder and CEO of Dyno Therapeutics. Combining next-generation DNA synthesis of millions of AAV capsids with high-throughput sequencing and machine learning, Dyno is using a data-driven approach to create novel adeno-associated virus (AAV) vectors that enable the safe, efficient and targeted  in vivo  delivery of revolutionary gene therapies. Eric received his PhD at Harvard University in the lab of Dr. Roy Kishony and completed is postdoc in the lab of Dr. George Church. While in the Church lab Eric developed high-throughput multiplexed methods for improving gene therapy and applied new protein engineering methods to improve AAV for gene therapy.

Eric Kelsic, PhD is the Cofounder and CEO of Dyno Therapeutics. Combining next-generation DNA synthesis of millions of AAV capsids with high-throughput sequencing and machine learning, Dyno is using a data-driven approach to create novel adeno-associated virus (AAV) vectors that enable the safe, efficient and targeted in vivo delivery of revolutionary gene therapies. Eric received his PhD at Harvard University in the lab of Dr. Roy Kishony and completed is postdoc in the lab of Dr. George Church. While in the Church lab Eric developed high-throughput multiplexed methods for improving gene therapy and applied new protein engineering methods to improve AAV for gene therapy.

Omar Abudayyeh, PhD & Jonathan Gootenberg, PhD  are co-founders of Sherlock Biosciences. Based upon technology they developed in the Zhang lab (SHERLOCK) and work in the Collins Lab (INSPECTR), Sherlock Biosciences is leveraging CRISPR-based engineering and synthetic biology platforms to create a new generation of rapid, accurate molecular diagnostics. Launching with $35M, Sherlock has assembled a worldclass team of nine co-founders including CRISPR pioneers, industry veterans, and disease experts.

Omar Abudayyeh, PhD & Jonathan Gootenberg, PhD are co-founders of Sherlock Biosciences. Based upon technology they developed in the Zhang lab (SHERLOCK) and work in the Collins Lab (INSPECTR), Sherlock Biosciences is leveraging CRISPR-based engineering and synthetic biology platforms to create a new generation of rapid, accurate molecular diagnostics. Launching with $35M, Sherlock has assembled a worldclass team of nine co-founders including CRISPR pioneers, industry veterans, and disease experts.